Skip to content
    Guidelines & Consensus

    Comparing EAU-ASCO, NCCN, and ESMO Guidelines for Penile Cancer Management and Methodological Rigor

    Pandolfo et alMinerva Urology and Nephrology

    International guidelines represent the cornerstone of therapeutic decision-making for penile cancer, a rare malignancy characterized by geographic variability and a paucity of large-scale clinical trials. A comparative analysis and methodological appraisal evaluated three leading international clinical practice guidelines: the EAU-ASCO (2025), NCCN (2025), and ESMO (2024) guidelines. Two independent uro-oncology experts assessed four core clinical domains—primary tumor management, lymph node evaluation and treatment, systemic therapy, and surveillance protocols—while two independent reviewers applied the standardized AGREE II instrument across 23 items and six domains to grade guideline development rigor.
    Clinical analysis identified strong consensus on the initial management of early-stage tumors and the implementation of platinum-based chemotherapy regimens for advanced disease. In contrast, prominent divergences emerged in recommendations governing surgical margin requirements, specific diagnostic and interventional thresholds for regional lymph node assessment, second-line systemic regimens, and follow-up intervals.
    Methodological evaluation via AGREE II demonstrated marked differences in guideline development quality among organizations. EAU-ASCO achieved the highest standardized quality scores across all six domains, followed in descending order by NCCN and ESMO. The analysis was limited by the exclusion of regional guidelines outside these major bodies and by baseline heterogeneity across the evidence-grading systems employed within each guideline.

    Key Takeaways

    • In an AGREE II methodological appraisal of international penile cancer guidelines, EAU-ASCO (2025) scored highest across all evaluated quality domains, outperforming NCCN (2025) and ESMO (2024).
    • While major guidelines demonstrate substantial consensus on early-stage primary tumor management and frontline platinum-based chemotherapy for advanced disease, significant discrepancies persist regarding surgical margin definitions, lymph node evaluation thresholds, second-line systemic therapies, and follow-up schedules.
    Read the original sourceMinerva Urology and Nephrology